New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
A roundup of the first quarter's key oncology drug approvals and rejections.
The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.
The latest first-in-human study initiations will be of interest to followers of D2M Therapeutics, Nested and Volastra.